일본의 당뇨병약 시장 보고서 : 유형별, 유통 채널별, 지역별(2025-2033년)

Japan Diabetes Drugs Market Report by Type (Insulins, Oral Anti-diabetic Drugs, Non-Insulin Injectable Drugs, Combination Drugs), Distribution Channel (Online Pharmacies, Hospital Pharmacies Retail Pharmacies), and Region 2025-2033

US $ 2,999 ￦ 4,351,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 3,999 ￦ 5,802,000

PDF & Excel (5 User License)

PDF, Excel 보고서를 동일 사업장의 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,999 ￦ 7,253,000

PDF & Excel (Corporate License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

일본의 당뇨병약 시장의 시장 규모는 2024년에 44억 달러에 달했습니다. IMARC Group은 2025-2033년 성장률(CAGR)이 3.5%로, 2033년에는 59억 달러에 달할 것으로 예측하고 있습니다. 혈당치를 효과적으로 컨트롤하는 것을 목적으로 한 다양한 당뇨병약의 개발, 제조, 판매에 종사하는 제약 기업의 수가 증가하고 있는 것이 주로 시장 성장의 원동력이 되고 있습니다.

본 리포트에서 답변하는 주요 질문

• 일본의 당뇨병약 시장의 지금까지 실적과 향후 실적은?
• 일본의 당뇨병약시장에 대한 COVID-19의 영향은?
• 일본의 당뇨병약 시장의 유형별 내역은?
• 일본의 당뇨병약 시장의 유통 채널별 내역은?
• 일본의 당뇨병약 시장의 밸류체인에는 어떤 단계가 있는가?
• 일본의 당뇨병약의 주요 촉진요인과 과제는?
• 일본의 당뇨병약 시장의 구조와 주요 기업은?
• 일본의 당뇨병약시장에서 경쟁의 정도는?

목차

제1장 서문

제2장 조사 범위와 조사 방법

• 조사의 목적
• 이해관계자
• 데이터 소스
• 시장 추정
• 조사 방법

제3장 개요

제4장 일본의 당뇨병약시장 : 서론

• 개요
• 시장 역학
• 업계 동향
• 경쟁 정보

제5장 일본의 당뇨병약 시장 구도

• 과거 및 현재 시장 동향(2019-2024년)
• 시장 예측(2025-2033)

제6장 일본의 당뇨병약시장 : 유형별 내역

• 인슐린
• 경구항당뇨병약
• 비인슐린 주사약
• 병용약

제7장 일본의 당뇨병약시장 : 유통 채널별 내역

• 온라인 약국
• 병원 약국
• 소매 약국

제8장 일본의 당뇨병약시장 : 경쟁 구도

• 개요
• 시장 구조
• 시장 기업 포지셔닝
• 주요 성공 전략
• 경쟁 대시보드
• 기업 평가 상한

제9장 주요 기업의 개요

제10장 일본의 당뇨병약시장 : 업계 분석

• 촉진요인·억제요인·기회
• Porter's Five Forces 분석
• 밸류체인 분석

제11장 부록

KSA

영문 목차

영문목차

Japan diabetes drugs market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.9 Billion by 2033, exhibiting a growth rate (CAGR) of 3.5% during 2025-2033. The rising number of established pharmaceutical companies engaged in the development, production, and distribution of a diverse range of diabetes medications, each aiming to control blood glucose levels effectively is primarily driving the market growth.

Diabetes drugs play a pivotal role in managing and treating diabetes, a chronic condition characterized by elevated blood sugar levels due to the body's inability to produce sufficient insulin or utilize it effectively. These pharmaceutical agents are crucial in controlling the progression of the disease and mitigating the risk of complications, such as cardiovascular disease, kidney damage, and vision loss. There are various classes of diabetes drugs, each working differently to regulate blood glucose levels. Some are designed to boost insulin secretion, while others improve insulin sensitivity or decrease the amount of glucose absorbed by the intestines.

Japan Diabetes Drugs Market Trends:

The Japan diabetes drugs market is a rapidly evolving sector, responding to the escalating need stemming from the widespread prevalence of diabetes in the region, predominantly influenced by aging demographics and lifestyle alterations. The dynamics of this market are shaped by the infusion of innovative solutions and relentless research endeavors by prominent pharmaceutical entities, aimed at devising diverse medication strategies to meticulously regulate blood glucose levels. The market is experiencing substantial growth, fueled by a heightened awareness and understanding of diabetes and its associated complications. The propensity towards embracing novel and effective diabetes medications is prominent in Japan, with a significant inclination towards the integration of advanced drugs, such as GLP-1 receptor agonists, which are gaining traction due to their efficacy and multifunctionality in managing blood sugar levels and weight. A distinctive trend in the market is the burgeoning investment in R&D activities, fostering the development of groundbreaking drugs with enhanced capabilities and reduced side effects. The advent of personalized medicine is also playing a pivotal role in shaping the market landscape, enabling more tailored and patient-centric approaches to treatment. The heightened emphasis on healthcare and wellness, coupled with supportive regulatory frameworks and substantial healthcare expenditure, is anticipated to propel the regional market forward over the forecasted period.

Japan Diabetes Drugs Market Segmentation:

Type Insights:

• Insulins
• Basal or Long Acting Insulins
• Lantus (Insulin Glargine)
• Levemir (Insulin Detemir)
• Toujeo (Insulin Glargine)
• Tresiba (Insulin Degludec)
• Basaglar (Insulin Glargine)
• Bolus or Fast Acting Insulins
• NovoRapid/Novolog (Insulin Aspart)
• Humalog (Insulin Lispro)
• Apidra (Insulin Glulisine)
• Traditional Human Insulins
• Novolin/Actrapid/Insulatard
• Humulin
• Insuman
• Biosimilar Insulins
• Insulin Glargine Biosimilars
• Human Insulin Biosimilars
• Oral Anti-diabetic Drugs
• Biguanides
• Metformin
• Alpha-Glucosidase Inhibitors
• Dopamine D2 Receptor Agonist
• Bromocriptin
• SGLT-2 Inhibitor
• Invokana (Canagliflozin)
• Jardiance (Empagliflozin)
• Farxiga/Forxiga (Dapagliflozin)
• Suglat (Ipragliflozin)
• DPP-4 Inhibitors
• Onglyza (Saxagliptin)
• Tradjenta (Linagliptin)
• Vipidia/Nesina (Alogliptin)
• Galvus (Vildagliptin)
• Sulfonylureas
• Meglitinides
• Non-Insulin Injectable Drugs
• GLP-1 Receptor Agonists
• Victoza (Liraglutide)
• Byetta (Exenatide)
• Bydureon (Exenatide)
• Trulicity (Dulaglutide)
• Lyxumia (Lixisenatide)
• Amylin Analogue
• Symlin (Pramlintide)
• Combination Drugs
• Insulin Combinations
• NovoMix (Biphasic Insulin Aspart)
• Ryzodeg (Insulin Degludec and Insulin Aspart)
• Xultophy (Insulin Degludec and Liraglutide)
• Oral Combination
• Janumet (Sitagliptin and Metformin)

Distribution Channel Insights:

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan diabetes drugs market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan diabetes drugs market?
• What is the breakup of the Japan diabetes drugs market on the basis of type?
• What is the breakup of the Japan diabetes drugs market on the basis of distribution channel?
• What are the various stages in the value chain of the Japan diabetes drugs market?
• What are the key driving factors and challenges in the Japan diabetes drugs?
• What is the structure of the Japan diabetes drugs market and who are the key players?
• What is the degree of competition in the Japan diabetes drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Diabetes Drugs Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Diabetes Drugs Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Diabetes Drugs Market - Breakup by Type

• 6.1 Insulins
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Segmentation
    • 6.1.3.1 Basal or Long Acting Insulins
      • 6.1.3.1.1 Lantus (Insulin Glargine)
      • 6.1.3.1.2 Levemir (Insulin Detemir)
      • 6.1.3.1.3 Toujeo (Insulin Glargine)
      • 6.1.3.1.4 Tresiba (Insulin Degludec)
      • 6.1.3.1.5 Basaglar (Insulin Glargine)
    • 6.1.3.2 Bolus or Fast Acting Insulins
      • 6.1.3.2.1 NovoRapid/Novolog (Insulin Aspart)
      • 6.1.3.2.2 Humalog (Insulin Lispro)
      • 6.1.3.2.3 Apidra (Insulin Glulisine)
    • 6.1.3.3 Traditional Human Insulins
      • 6.1.3.3.1 Novolin/Actrapid/Insulatard
      • 6.1.3.3.2 Humulin
      • 6.1.3.3.3 Insuman
    • 6.1.3.4 Biosimilar Insulins
      • 6.1.3.4.1 Insulin Glargine Biosimilars
      • 6.1.3.4.2 Human Insulin Biosimilars
  • 6.1.4 Market Forecast (2025-2033)
• 6.2 Oral Anti-diabetic Drugs
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Segmentation
    • 6.2.3.1 Biguanides
      • 6.2.3.1.1 Metformin
    • 6.2.3.2 Alpha-Glucosidase Inhibitors
    • 6.2.3.3 Dopamine D2 Receptor Agonist
      • 6.2.3.3.1 Bromocriptin
    • 6.2.3.4 SGLT-2 Inhibitors
      • 6.2.3.4.1 Invokana (Canagliflozin)
      • 6.2.3.4.2 Jardiance (Empagliflozin)
      • 6.2.3.4.3 Farxiga/Forxiga (Dapagliflozin)
      • 6.2.3.4.4 Suglat (Ipragliflozin)
    • 6.2.3.5 DPP-4 Inhibitors
      • 6.2.3.5.1 Onglyza (Saxagliptin)
      • 6.2.3.5.2 Tradjenta (Linagliptin)
      • 6.2.3.5.3 Vipidia/Nesina (Alogliptin)
      • 6.2.3.5.4 Galvus (Vildagliptin)
    • 6.2.3.6 Sulfonylureas
    • 6.2.3.7 Meglitinides
  • 6.2.4 Market Forecast (2025-2033)
• 6.3 Non-Insulin Injectable Drugs
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2019-2024)
  • 6.3.3 Market Segmentation
    • 6.3.3.1 GLP-1 Receptor Agonists
      • 6.3.3.1.1 Victoza (Liraglutide)
      • 6.3.3.1.2 Byetta (Exenatide)
      • 6.3.3.1.3 Bydureon (Exenatide)
      • 6.3.3.1.4 Trulicity (Dulaglutide)
      • 6.3.3.1.5 Lyxumia (Lixisenatide)
    • 6.3.3.2 Amylin Analogue
      • 6.3.3.2.1 Symlin (Pramlintide)
  • 6.3.4 Market Forecast (2025-2033)
• 6.4 Combination Drugs
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2019-2024)
  • 6.1.2 Market Segmentation
    • 6.3.3.1 Insulin Combinations
      • 6.3.3.1.1 NovoMix (Biphasic Insulin Aspart)
      • 6.3.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
      • 6.3.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
    • 6.3.3.2 Oral Combinations
      • 6.3.3.2.1 Janumet (Sitagliptin and Metformin)
  • 6.4.4 Market Forecast (2025-2033)

7 Japan Diabetes Drugs Market - Breakup by Distribution Channel

• 7.1 Online Pharmacies
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Hospital Pharmacies
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)
• 7.3 Retail Pharmacies
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2019-2024)
  • 7.3.3 Market Forecast (2025-2033)

8 Japan Diabetes Drugs Market - Competitive Landscape

• 8.1 Overview
• 8.2 Market Structure
• 8.3 Market Player Positioning
• 8.4 Top Winning Strategies
• 8.5 Competitive Dashboard
• 8.6 Company Evaluation Quadrant

9 Profiles of Key Players

• 9.1 Company A
  • 9.1.1 Business Overview
  • 9.1.2 Product Portfolio
  • 9.1.3 Business Strategies
  • 9.1.4 SWOT Analysis
  • 9.1.5 Major News and Events
• 9.2 Company B
  • 9.2.1 Business Overview
  • 9.2.2 Product Portfolio
  • 9.2.3 Business Strategies
  • 9.2.4 SWOT Analysis
  • 9.2.5 Major News and Events
• 9.3 Company C
  • 9.3.1 Business Overview
  • 9.3.2 Product Portfolio
  • 9.3.3 Business Strategies
  • 9.3.4 SWOT Analysis
  • 9.3.5 Major News and Events
• 9.4 Company D
  • 9.4.1 Business Overview
  • 9.4.2 Product Portfolio
  • 9.4.3 Business Strategies
  • 9.4.4 SWOT Analysis
  • 9.4.5 Major News and Events
• 9.5 Company E
  • 9.5.1 Business Overview
  • 9.5.2 Product Portfolio
  • 9.5.3 Business Strategies
  • 9.5.4 SWOT Analysis
  • 9.5.5 Major News and Events

10 Japan Diabetes Drugs Market - Industry Analysis

• 10.1 Drivers, Restraints, and Opportunities
  • 10.1.1 Overview
  • 10.1.2 Drivers
  • 10.1.3 Restraints
  • 10.1.4 Opportunities
• 10.2 Porters Five Forces Analysis
  • 10.2.1 Overview
  • 10.2.2 Bargaining Power of Buyers
  • 10.2.3 Bargaining Power of Suppliers
  • 10.2.4 Degree of Competition
  • 10.2.5 Threat of New Entrants
  • 10.2.6 Threat of Substitutes
• 10.3 Value Chain Analysis

11 Appendix

관련자료